Kristie Blum A MD


Kristie Blum A MD
Assoc ProfessorCollege of Medicineblum.50@osu.edu
B324 Starling Loving Hall 320 W 10th Avenue Columbus Ohio 43210
Phone:614-293-7807Fax: (614) 293-7525
  • Leukemia Research

Research Description

Dr. Blum's clinical research includes B-cell non-Hodgkins lymphoma, Hodgkin's lymphoma, Hairy cell leukemia, Waldenstrom’s macroglobulinemia and her research interests include Burkitt’s lymphoma, Mantle Cell Lymphoma, Diffuse large B-cell lymphoma, Hodgkin’s lymphoma

Current Publications

  • Woyach JA, Barrientos JC, Lichter P, Stilgenbauer S, Buggy JJ, Chang BY, Johnson AJ, Byrd JC, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, Xue L, Li DH, Steggerda SM, Versele M, Dave SS, Zhang J, Yilmaz AS, Jaglowski SM, Blum KA, Lozanski A, Lozanski G, James DFResistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.N Engl J Med 370 2286-94 6/12/2014
  • Maddocks K, Blum KAIbrutinib in B-cell Lymphomas.Curr Treat Options Oncol 15 226-37 6/1/2014
  • Cohen JB, Geyer SM, Lozanski G, Zhao W, Heerema NA, Hall NC, Nagar VA, Hemminger JA, Jones JA, Porcu P, Christian BA, Baiocchi RA, Maddocks KJ, Flynn JM, Devine SM, Blum KAComplete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival.Cancer 120 1677-85 6/1/2014
  • Shea TC, Nattam S, Hoke E, Cheson BD, Larson RA, Alliance for Clinical Trials In Oncology (ACTION), Rizzieri DA, Johnson JL, Byrd JC, Lozanski G, Blum KA, Powell BLImproved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002.Br J Haematol 165 102-11 4/1/2014
  • Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, Flinn IW, Flowers CR, Martin P, Viardot A, Blum KA, Goy AH, Davies AJ, Zinzani PL, Dreyling M, Johnson D, Miller LL, Holes L, Li D, Dansey RD, Godfrey WR, Salles GAPI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.N Engl J Med 370 1008-18 3/13/2014
  • O'Brien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA, Grant B, Izumi R, Hamdy A, Chang BY, Graef T, Clow F, Buggy JJ, James DF, Byrd JC, Richards DA, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJIbrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.Lancet Oncol 15 48-58 1/1/2014
  • Poi M, Phelps MA, Andritsos L, Baiocchi R, Benson DM, Jones JA, Rupert AS, Blum KA, Christian B, Flynn J, Penza S, Porcu P, Grever MR, Byrd JCFlavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma.Am J Hematol 89 19-24 1/1/2014
  • Vose JM, Hernandez-Ilizaliturri FJ, Robinson BK, Otis S, Nadav Dagan L, Abdallah R, Kroll-Desrosiers A, Yarber JL, Sandoval J, Foyil K, Parker LM, Gordon LI, Blum KA, Flowers CR, Leonard JP, Habermann TM, Bartlett NL, Evens AM, Advani R, Press OW, Lossos ISLymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis.J Clin Oncol 31 4132-9 11/10/2013
  • Binkley P, Byrd JC, Grever MR, Garzon R, Phelps MA, Marcucci G, Blum KA, Blum W, Walker AR, Klisovic R, Johnston JS, Jiang Y, Geyer S, Kefauver CPharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia.Leuk Lymphoma 54 1996-2002 9/1/2013
  • Cohen JB, Hall NC, Ruppert AS, Jones JA, Porcu P, Baiocchi R, Christian BA, Penza S, Benson DM Jr, Flynn J, Andritsos LA, Devine SM, Blum KAAssociation of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell lymphoma.Bone Marrow Transplant 48 1212-7 9/1/2013
  • Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA, Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling MTargeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.N Engl J Med 369 507-16 8/8/2013
  • Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Sukbuntherng J, Chang BY, Clow F, Hedrick E, Buggy JJ, James DF, O'Brien STargeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.N Engl J Med 369 32-42 7/4/2013
  • Ji J, Mould DR, Blum KA, Ruppert AS, Poi M, Zhao Y, Johnson AJ, Byrd JC, Grever MR, Phelps MAA pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol.Clin Cancer Res 19 1269-80 3/1/2013
  • Stiff PJ, Cheson BD, Gospodarowicz M, Advani R, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ, Gordon LI, Hong F, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner HRandomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496).J Clin Oncol 31 684-91 2/20/2013

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu